Companies · · 3 min read
Editor: Bohdan S.
CVS Health plans to split off its drugstores from Aetna and Caremark
CVS Health will separate its roughly 9,000 pharmacies from its insurance and drug-benefit arms by 2028. Shares fell more than 10% on Wednesday despite better-than-expected results.
The short answer
CVS Health said on Wednesday it will split into two listed companies by the first half of 2028: one keeping Aetna and the Caremark drug-benefit business, the other running about 9,000 CVS pharmacies. The plan undoes the integrated model built around its 2018 Aetna purchase. Shares fell more than 10%, CNBC reported.
What happened
According to the company's announcement, CVS Health intends to separate into two independent, publicly traded businesses in a deal designed to be tax-free for US federal income tax purposes. One, still called CVS Health and run by chief executive David Joyner, will hold insurer Aetna, pharmacy benefit manager CVS Caremark, CVS Specialty, Oak Street Health and Signify Health. The other, named CVS Pharmacy and led by group president Prem Shah, will hold the stores, mail pharmacy, MinuteClinic and Health100. Existing investors will receive shares in both. Completion still needs final board approval, an effective Form 10 registration with the SEC and confirmation of the tax treatment. CNBC reported the stock dropped more than 10% on Wednesday.
What it means
This is a sharp change of direction. For about two decades CVS tried to become a one-stop health company, and its $78 billion takeover of Aetna in 2018 was the centerpiece, CNBC noted. Putting the insurer, the pharmacy benefit manager (PBM, the middleman that negotiates drug prices for employers and insurers) and the drugstores under one roof was meant to create savings. Now the board, after what the company called a comprehensive strategic review, has concluded the parts will do better on their own.
Timing matters. CVS looked at a breakup once before, in October 2024, but Joyner told CNBC the company was then in a turnaround and lacked the cash and performance to pull it off. Since he took charge that month, the stock has gained roughly 70%, lifting its market value to $117 billion, according to CNBC. Joyner described the decision as coming "out of a position of strength," citing a recovery in Aetna's Medicare business and steady results at the stores.
The same day, CVS posted third-quarter results that beat Wall Street expectations. Revenue climbed 5.4% to $108.4 billion and adjusted earnings per share rose to $2.09 from $1.60, according to the company's release. Aetna's medical benefit ratio, the share of premiums paid out for care, improved to 91.3% from 92.8%. CVS raised its 2026 outlook to adjusted earnings of at least $8.20 a share and operating cash flow of at least $15.5 billion, though it kept a cautious tone because of high medical cost trends. One weak spot: revenue in the pharmacy and consumer wellness unit fell 2.0%.
Politics is part of the backdrop. PBMs face criticism from both parties in Washington and in state capitals over opaque pricing and possible conflicts of interest when one company also owns insurers and pharmacies. CNBC reported that Tennessee and Arkansas have passed laws that would ban joint ownership of PBMs and pharmacies, which CVS and others are challenging in court. Leerink Partners analyst Michael Cherny told CNBC that this scrutiny could be part of the reason for the split, and that the pharmacy business has stabilized, helped by CostVantage, a newer reimbursement model CVS describes as more transparent.
The bull case
Supporters would say two focused companies are easier to value and manage than one sprawling group. CVS expects both to keep investment-grade credit ratings and enough free cash flow to fund investment and dividends. The split could also ease regulatory pressure on combined pharmacy and PBM ownership, and Joyner says commercial agreements between the two firms will keep the main benefits of working together.
The bear case
Skeptics worry the drugstore chain could lose a key advantage once it is no longer tied to a large PBM that steers prescriptions its way, and its revenue is already shrinking. A separation this big costs money and management attention, and it will not be finished until 2028. Wednesday's share drop suggests many investors are not yet convinced the parts are worth more than the whole.
Why it matters
For investors
CVS shares took the hit on Wednesday, and the plan keeps a spotlight on health insurers, PBMs and pharmacy chains as lawmakers scrutinize vertically integrated healthcare groups.
The wider context
For shareholders, the breakup means eventually holding two separate stocks with different risks. For patients and employers, CVS says the pharmacy and drug-benefit businesses will keep working together through contracts rather than shared ownership.
Market impact
| Asset (ticker) | Possible move | Timeframe | Why |
|---|---|---|---|
| CVS Health (CVS) | ↓ Down | Short term | Stock fell more than 10% Wednesday as investors questioned the costly, multi-year breakup plan. |
The FinPrism newsroom's view of how these figures could move, as of . It is general news commentary, not a recommendation to buy, sell or hold anything.
Frequently asked questions
Why is CVS splitting into two companies?
CVS says separate companies will each have a sharper strategy and more freedom to invest, adopt technology and improve efficiency. Its board reached the decision after a strategic review. Analysts also point to growing political scrutiny of firms that own both a pharmacy benefit manager and pharmacies, which some states are trying to ban.
What happens to CVS shareholders after the split?
Current CVS investors will end up owning shares in both new companies: CVS Health, which keeps Aetna and Caremark, and CVS Pharmacy, which runs the stores. The company intends the separation to be tax-free for US federal income tax purposes. It is expected to be completed in the first half of 2028.
Why did CVS stock fall after announcing the breakup?
Shares dropped more than 10% on Wednesday, according to CNBC, even though quarterly results beat expectations and guidance was raised. Investors may be concerned about the cost and length of the separation, and about whether the drugstore chain can compete without being directly linked to the Caremark drug-benefit business.
Sources: CVS Health company releases (Stock Titan), CNBC
How this was made: written with AI assistance from the sources listed above, following our editorial standards.